ATE498689T1 - Methode für die produktion von retroviralen verpackungszellinien, die einen retroviralen überstand mit hocheffizienter transduktionsrate produzieren - Google Patents

Methode für die produktion von retroviralen verpackungszellinien, die einen retroviralen überstand mit hocheffizienter transduktionsrate produzieren

Info

Publication number
ATE498689T1
ATE498689T1 AT96945101T AT96945101T ATE498689T1 AT E498689 T1 ATE498689 T1 AT E498689T1 AT 96945101 T AT96945101 T AT 96945101T AT 96945101 T AT96945101 T AT 96945101T AT E498689 T1 ATE498689 T1 AT E498689T1
Authority
AT
Austria
Prior art keywords
retroviral
supernatant
pct
packaging cell
recombinant
Prior art date
Application number
AT96945101T
Other languages
English (en)
Inventor
Richard Rigg
Jingyi Chen
Jonathan Dando
Ivan Plavec
Sean Forestell
Ernst Bohnlein
Original Assignee
Systemix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systemix Inc filed Critical Systemix Inc
Application granted granted Critical
Publication of ATE498689T1 publication Critical patent/ATE498689T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hybrid Cells (AREA)
  • Led Devices (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Packages (AREA)
AT96945101T 1995-12-15 1996-12-13 Methode für die produktion von retroviralen verpackungszellinien, die einen retroviralen überstand mit hocheffizienter transduktionsrate produzieren ATE498689T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/572,959 US5910434A (en) 1995-12-15 1995-12-15 Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
PCT/US1996/020777 WO1997021825A1 (en) 1995-12-15 1996-12-13 Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant

Publications (1)

Publication Number Publication Date
ATE498689T1 true ATE498689T1 (de) 2011-03-15

Family

ID=24290077

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96945101T ATE498689T1 (de) 1995-12-15 1996-12-13 Methode für die produktion von retroviralen verpackungszellinien, die einen retroviralen überstand mit hocheffizienter transduktionsrate produzieren

Country Status (11)

Country Link
US (2) US5910434A (de)
EP (1) EP0871754B1 (de)
JP (1) JP2000501944A (de)
AT (1) ATE498689T1 (de)
AU (1) AU706543B2 (de)
CA (1) CA2238436C (de)
DE (1) DE69638334D1 (de)
DK (1) DK0871754T3 (de)
ES (1) ES2357736T3 (de)
PT (1) PT871754E (de)
WO (1) WO1997021825A1 (de)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020173643A1 (en) * 1995-04-14 2002-11-21 Kappes John C. Fusion protein delivery system and uses thereof
KR100503701B1 (ko) * 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2995542A1 (en) * 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US7033595B1 (en) 1998-08-04 2006-04-25 Purdue Research Foundation Pseudotyped retroviruses and stable cell lines for their production
ES2541540T3 (es) * 1998-09-04 2015-07-21 Genzyme Corporation Métodos para generar preparados exentos de helper de alto título de vectores de AAV recombinantes liberados
EP2942393A1 (de) 1998-09-04 2015-11-11 Genzyme Corporation Verfahren zur erzeugung helferfreier präparate mit hohem titer aus freigesetzten rekombinanten aav-vektoren
CA2374745A1 (en) * 1999-08-09 2001-02-15 Incyte Genomics, Inc. Proteases and protease inhibitors
AU7353500A (en) * 1999-09-10 2001-04-10 Incyte Genomics, Inc. Apoptosis proteins
US6790614B1 (en) 1999-11-19 2004-09-14 Novartis Ag Selectable cell surface marker genes
EP1282727A1 (de) 2000-02-25 2003-02-12 Biofocus Discovery Limited Verfahren zum identifizieren von potentielle protease-kodierende polynukleotide
EP1259611A2 (de) * 2000-03-03 2002-11-27 Incyte Genomics, Inc. G-protein gekoppelter rezeptoren
US6849454B2 (en) 2000-03-07 2005-02-01 St. Jude Children's Research Hospital Highly efficient gene transfer into human repopulating stem cells by RD114 pseudotyped retroviral vector particles
US20040086877A1 (en) 2000-06-16 2004-05-06 Lal Preeti G. Multi-mode directi memory access controller and method
US7608704B2 (en) 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
NZ527687A (en) * 2001-05-11 2005-10-28 Wellstat Biolog Corp Formerly Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer
WO2003102219A2 (en) * 2002-06-04 2003-12-11 Purdue Research Foundation Improved pseudotyped retroviruses
WO2003070902A2 (en) * 2002-02-20 2003-08-28 Incyte Corporation Receptors and membrane-associated proteins
US20040009158A1 (en) * 2002-07-11 2004-01-15 Washington University Promotion of neovascularization using bone marrow-derived endothelial-progenitor cells
US20070276126A1 (en) * 2002-08-13 2007-11-29 Incyte Corporation Cell adhesion and extracellular matrix proteins
US20070219353A1 (en) * 2002-09-03 2007-09-20 Incyte Corporation Immune Response Associated Proteins
WO2004033636A2 (en) * 2002-10-04 2004-04-22 Incyte Corporation Protein modification and maintenance molecules
US20050164275A1 (en) * 2002-10-18 2005-07-28 Incyte Corporation Phosphodiesterases
US20070009886A1 (en) * 2002-11-12 2007-01-11 Incyte Corporation Carbohydrate-associated proteins
US20070065820A1 (en) * 2002-11-13 2007-03-22 Xin Jiang Lipid-associated molecules
WO2004048550A2 (en) * 2002-11-26 2004-06-10 Incyte Corporation Immune response associated proteins
US7829682B1 (en) 2003-04-30 2010-11-09 Incyte Corporation Human β-adrenergic receptor kinase nucleic acid molecule
WO2005047497A1 (en) * 2003-11-12 2005-05-26 Universite Laval High-titer retroviral packaging cells
EP1807510A4 (de) 2004-09-24 2008-01-23 Angioblast Systems Inc Memp (multipotential expanded mesenchymal precursor cell progeny) und verwendungen davon
KR20130100225A (ko) 2004-09-24 2013-09-09 안지오블라스트 시스템스 인코퍼레이티드 간엽 전구세포의 증식 및/또는 생존성 증강 방법
US8325826B2 (en) * 2005-03-09 2012-12-04 Qualcomm Incorporated Methods and apparatus for transmitting signals facilitating antenna control
US7826807B2 (en) * 2005-03-09 2010-11-02 Qualcomm Incorporated Methods and apparatus for antenna control in a wireless terminal
KR101446634B1 (ko) 2005-04-12 2014-10-16 메소블라스트, 아이엔씨. 조직 비특이적인 알카리 포스파타제에 의한 다분화성 성체세포의 분리
US20070020238A1 (en) * 2005-06-01 2007-01-25 David Baltimore Method of targeted gene delivery using viral vectors
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US8129187B2 (en) * 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
EP2208786B1 (de) * 2005-12-13 2018-08-01 Kyoto University Nukleärer Reprogrammierungsfaktor
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8034335B2 (en) * 2006-04-28 2011-10-11 Universite Laval High-titer retroviral packaging cells
US7720485B2 (en) * 2006-07-14 2010-05-18 Qualcomm Incorporated Methods and apparatus related to assignment in a wireless communications system
US7724853B2 (en) * 2006-07-14 2010-05-25 Qualcomm Incorporated Enabling mobile switched antennas
US8225186B2 (en) 2006-07-14 2012-07-17 Qualcomm Incorporated Ecoding and decoding methods and apparatus for use in a wireless communication system
PT2520168E (pt) * 2006-07-21 2014-04-29 California Inst Of Techn Administração de gene alvo para vacinação de células dendríticas
ES2569365T3 (es) 2006-11-29 2016-05-10 Nationwide Children's Hospital Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular
WO2008137641A2 (en) 2007-05-04 2008-11-13 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9213999B2 (en) * 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP6062615B2 (ja) 2007-08-06 2017-01-18 メゾブラスト，インコーポレーテッド インビボで結合組織を生成、修復、および／または維持するための方法
TWI325401B (en) * 2007-12-17 2010-06-01 Duen Gang Mou Vessel structure
CA2695522C (en) * 2008-05-02 2019-01-15 Kyoto University Method of nuclear reprogramming
EP3121597A1 (de) 2008-08-18 2017-01-25 Mesoblast, Inc. Monoklonaler antikörper stro-4
US11219696B2 (en) 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
DK2770061T3 (en) 2009-07-24 2019-01-07 Immune Design Corp NON-INTEGRATING LENTIVIRUS VECTORS
AU2011332815A1 (en) 2010-11-23 2013-05-30 Presage Biosciences, Inc. Therapeutic methods and compositions for solid delivery
ES2702496T3 (es) 2011-04-21 2019-03-01 Nationwide Childrens Hospital Inc Productos de virus recombinante y procedimientos para la inhibición de la expresión de la miotilina
US10196636B2 (en) 2011-04-21 2019-02-05 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of myotilin
US20130039888A1 (en) 2011-06-08 2013-02-14 Nationwide Children's Hospital Inc. Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
WO2013016352A1 (en) 2011-07-25 2013-01-31 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of dux4
WO2013078316A1 (en) 2011-11-23 2013-05-30 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
MX362699B (es) 2012-03-30 2019-02-01 Immune Design Corp Partículas de vectores lentivirales teniendo eficiencia de transducción mejorada para células que expresan dc-sign.
PT2879719T (pt) 2012-08-01 2018-10-08 Ohio State Innovation Foundation Administração intratecal do vírus adeno-associado 9 recombinante
JP6901823B2 (ja) 2012-08-01 2021-07-14 ユナイテッド セラピューティクス コーポレイション 間葉系幹細胞による肺動脈性高血圧症の処置
WO2014022376A2 (en) 2012-08-01 2014-02-06 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
JP2015529685A (ja) 2012-09-17 2015-10-08 ザ・リサーチ・インスティテュート・アット・ネイションワイド・チルドレンズ・ホスピタルＴｈｅ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ａｔｎａｔｉｏｎｗｉｄｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ 筋萎縮性側索硬化症の処置のための組成物および方法
EP3878452B1 (de) 2013-01-09 2023-09-20 United Therapeutics Corporation Behandlung von vaskulopathie mit prostacyclin und mesenchymalen stammzellen
JP6461917B2 (ja) 2013-04-20 2019-01-30 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル エクソン２標的Ｕ７ｓｎＲＮＡポリヌクレオチド構築物の組換えアデノ随伴ウイルスによる送達
ES2901383T3 (es) 2013-05-10 2022-03-22 Whitehead Inst Biomedical Res Producción in vitro de glóbulos rojos con proteínas marcables con sortasa
PT3702466T (pt) 2013-08-27 2023-01-24 Res Inst Nationwide Childrens Hospital Produtos e métodos para tratamento de esclerose lateral amiotrófica
AU2014346987A1 (en) 2013-11-05 2016-06-23 The Research Institute At Nationwide Children's Hospital Compositions and methods for inhibiting NF-kB and SOD-1 to treat amyotrophic lateral sclerosis
US10047130B2 (en) 2014-03-18 2018-08-14 Washington University Methods and compositions for red-shifted chromophore substitution for optogenetic applications
CN114395559A (zh) * 2014-04-25 2022-04-26 吉尼松公司 高胆红素血症的治疗
AU2015301978C1 (en) 2014-08-09 2022-06-09 Research Institute At Nationwide Children's Hospital Methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene
US10842886B2 (en) 2014-10-10 2020-11-24 Research Institute At Nationwide Children's Hospital Guided injections for AAV gene transfer to muscle
EP3690024A1 (de) 2014-11-05 2020-08-05 The Research Institute at Nationwide Children's Hospital Verfahren und materialien zur herstellung rekombinanter viren in eukaryotischen mikroalgen
MA41451A (fr) 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
CN107532182A (zh) 2015-02-23 2018-01-02 克里斯珀医疗股份公司 治疗血红蛋白病的材料和方法
EP3281151B1 (de) * 2015-04-10 2023-03-29 President and Fellows of Harvard College Verfahren und vorrichtungen zur bildgebungsanalyse lebender zellen
US10017832B2 (en) 2015-08-25 2018-07-10 Washington University Compositions and methods for site specific recombination at asymmetric sites
EP3350331A4 (de) 2015-09-17 2019-01-23 Research Institute at Nationwide Children's Hospital Verfahren und materialien für galgt2-gentherapie
CA2998287A1 (en) 2015-09-24 2017-04-20 Crispr Therapeutics Ag Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
AU2016344609B2 (en) 2015-10-28 2022-05-12 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of duchenne muscular dystrophy
CA2999649A1 (en) 2015-11-06 2017-05-11 Crispr Therapeutics Ag Materials and methods for treatment of glycogen storage disease type 1a
EP3377042A4 (de) 2015-11-16 2019-05-29 The Research Institute at Nationwide Children's Hospital Materialien und verfahren zur behandlung von titinbasierten myopathien und anderen titinopathien
EP3967758A1 (de) 2015-12-01 2022-03-16 CRISPR Therapeutics AG Materialien und verfahren zur behandlung von alpha-1-antitrypsin-defizienz
WO2017106345A1 (en) 2015-12-14 2017-06-22 The Trustees Of The University Of Pennsylvania Composition for treatment of crigler-najjar syndrome
SG11201805320XA (en) 2015-12-23 2018-07-30 Crispr Therapeutics Ag Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
WO2017120589A1 (en) 2016-01-08 2017-07-13 Washington University Compositions comprising chemerin and methods of use thereof
WO2017134529A1 (en) 2016-02-02 2017-08-10 Crispr Therapeutics Ag Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
WO2017141109A1 (en) 2016-02-18 2017-08-24 Crispr Therapeutics Ag Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
WO2017147509A1 (en) 2016-02-25 2017-08-31 Marco Colonna Compositions comprising trem2 and methods of use thereof
EP3420109A4 (de) 2016-02-26 2019-11-06 Research Institute at Nationwide Children's Hospital Rekombinante virusprodukte und verfahren zur induktion von dux4-exon-skipping
WO2017158422A1 (en) 2016-03-16 2017-09-21 Crispr Therapeutics Ag Materials and methods for treatment of hereditary haemochromatosis
MA44528A (fr) 2016-04-02 2019-02-06 Res Inst Nationwide Childrens Hospital Système promoteur u6 modifié pour l'expression spécifique d'un tissu
CN109121395B (zh) 2016-04-15 2022-08-09 全国儿童医院研究所 腺相关病毒载体递送β-肌聚糖和微RNA-29以及肌营养不良症的治疗
MA45477A (fr) 2016-04-15 2019-02-20 Res Inst Nationwide Childrens Hospital Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire
SG10202010261YA (en) 2016-04-18 2020-11-27 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
WO2017191503A1 (en) 2016-05-05 2017-11-09 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
US11427838B2 (en) 2016-06-29 2022-08-30 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
US11174469B2 (en) 2016-06-29 2021-11-16 Crispr Therapeutics Ag Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
US11564997B2 (en) 2016-06-29 2023-01-31 Crispr Therapeutics Ag Materials and methods for treatment of friedreich ataxia and other related disorders
WO2018007976A1 (en) 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
CA3029141A1 (en) 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
WO2018007871A1 (en) 2016-07-08 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of transthyretin amyloidosis
WO2018020323A2 (en) 2016-07-25 2018-02-01 Crispr Therapeutics Ag Materials and methods for treatment of fatty acid disorders
IL266175B2 (en) 2016-10-24 2024-01-01 United Therapeutics Corp Enhancement of immunomodulatory properties of MSC using treprostinil
AU2017362491B2 (en) 2016-11-17 2023-02-02 Nationwide Children's Hospital Inc. Intrathecal delivery of recombinant Adeno-associated virus encoding Methyl-CpG binding protein 2
JP7206214B2 (ja) 2016-12-13 2023-01-17 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
EP3585895A1 (de) 2017-02-22 2020-01-01 CRISPR Therapeutics AG Zusammensetzungen und verfahren zur geneditierung
US11559588B2 (en) 2017-02-22 2023-01-24 Crispr Therapeutics Ag Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
US11407997B2 (en) 2017-02-22 2022-08-09 Crispr Therapeutics Ag Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
US20200216857A1 (en) 2017-02-22 2020-07-09 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
WO2018154418A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
EP3596112A2 (de) 2017-03-17 2020-01-22 Newcastle University Freisetzung eines adeno-assoziierten virusvektors eines fragments von mikrodystrophin zur behandlung von muskeldystrophie
PL3596222T3 (pl) 2017-03-17 2023-10-09 Research Institute At Nationwide Children's Hospital Dostarczanie z zastosowaniem wektora wirusa związanego z adenowirusami specyficznej dla mięśni mikrodystrofiny do leczenia dystrofii mięśniowej
WO2019097305A2 (en) 2017-05-12 2019-05-23 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
EP3652324A1 (de) 2017-07-08 2020-05-20 Genethon Behandlung von spinaler muskelatrophie
WO2019079527A1 (en) 2017-10-17 2019-04-25 Casebia Therapeutics Limited Liability Partnership COMPOSITIONS AND METHODS FOR GENETIC EDITION FOR HEMOPHILIA A
US11534501B2 (en) 2017-10-18 2022-12-27 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
CN111433367A (zh) 2017-10-20 2020-07-17 全国儿童医院研究所 Nt-3基因疗法的方法和材料
US20210180091A1 (en) 2017-10-26 2021-06-17 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
CA3082136A1 (en) 2017-11-08 2019-05-16 Avexis, Inc. Means and method for preparing viral vectors and uses of same
MA50578A (fr) 2017-11-09 2021-09-15 Vertex Pharma Systèmes crispr/cas pour le traitement de dmd
MA50877A (fr) 2017-11-21 2020-09-30 Bayer Healthcare Llc Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante
US11578323B2 (en) 2017-12-14 2023-02-14 Bayer Healthcare Llc RNA-programmable endonuclease systems and their use in genome editing and other applications
CA3084632A1 (en) 2017-12-21 2019-06-27 Crispr Therapeutics Ag Materials and methods for treatment of usher syndrome type 2a
WO2019123430A1 (en) 2017-12-21 2019-06-27 Casebia Therapeutics Llp Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
EP3737762A1 (de) 2018-01-12 2020-11-18 CRISPR Therapeutics AG Zusammensetzungen und verfahren zur geneditierung von genen durch transferrin-targeting
EP3749767A1 (de) 2018-02-05 2020-12-16 Vertex Pharmaceuticals Incorporated Materialien und verfahren zur behandlung von hämoglobinopathien
EP3749768A1 (de) 2018-02-05 2020-12-16 Vertex Pharmaceuticals Incorporated Materialien und verfahren zur behandlung von hämoglobinopathien
US20210130824A1 (en) 2018-02-16 2021-05-06 Crispr Therapeutics Ag Compositions and methods for gene editing by targeting fibrinogen-alpha
CN112424348A (zh) 2018-03-19 2021-02-26 克里斯珀医疗股份公司 新颖的rna-可编程的内切核酸酶系统及其用途
WO2019204668A1 (en) 2018-04-18 2019-10-24 Casebia Therapeutics Limited Liability Partnership Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
SG11202007874XA (en) 2018-04-27 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Rapamycin resistant cells
JP7478675B2 (ja) 2018-06-08 2024-05-07 ノバルティス アーゲー 薬物製品の効力を測定するための細胞ベースアッセイ
GB201809588D0 (en) 2018-06-12 2018-07-25 Univ Bristol Materials and methods for modulating intraocular and intracranial pressure
EP3807309A1 (de) 2018-06-18 2021-04-21 Research Institute at Nationwide Children's Hospital Rekombinante adeno-assoziierte virusprodukte und verfahren zur behandlung von dystroglycanopathien und von laminindefizienten muskeldystrophien
EP3807413A1 (de) 2018-06-18 2021-04-21 Research Institute at Nationwide Children's Hospital Adeno-assoziierte virusvektorverabreichung von muskelspezifischem mikrodystrophin zur behandlung von muskeldystrophie
MX2020014119A (es) 2018-06-29 2021-06-18 Res Inst Nationwide Childrens Hospital Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a.
WO2020047268A1 (en) 2018-08-29 2020-03-05 Research Institute At Nationwide Children's Hospital Products and methods for inhibition of expression of mutant gars protein
AU2019362000A1 (en) 2018-10-17 2021-05-20 Bayer Healthcare Llc Compositions and methods for delivering transgenes
BR112021009739A2 (pt) 2018-11-30 2021-10-19 Novartis Ag Vetores virais aav e usos dos mesmos
CA3122319A1 (en) 2018-12-21 2020-06-25 Genethon Expression cassettes for gene therapy vectors
EP3906308A1 (de) 2018-12-31 2021-11-10 Research Institute at Nationwide Children's Hospital Dux4-rna-ausschaltung unter verwendung von rna gegen crispr-cas13b
WO2020163300A1 (en) 2019-02-04 2020-08-13 Research Institute At Nationwide Children's Hospital Adeno-associated virus delivery of cln3 polynucleotide
US20220202956A1 (en) 2019-02-04 2022-06-30 Research Institute At Nationwide Children's Hospital Adeno-associated virus delivery of cln6 polynucleotide
MA54951A (fr) 2019-02-15 2021-12-22 Bayer Healthcare Llc Édition de gène pour l'hémophilie a avec une expression de facteur viii améliorée
WO2020176614A1 (en) 2019-02-26 2020-09-03 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy
MA55297A (fr) 2019-03-12 2022-01-19 Bayer Healthcare Llc Nouveaux systèmes d'endonucléase à arn programmable haute fidélité et leurs utilisations
AU2020257208A1 (en) 2019-04-15 2021-11-11 Research Institute At Nationwide Children's Hospital Gene therapy for treating or preventing visual effects in Batten disease
US20210047649A1 (en) 2019-05-08 2021-02-18 Vertex Pharmaceuticals Incorporated Crispr/cas all-in-two vector systems for treatment of dmd
WO2020236352A1 (en) 2019-05-17 2020-11-26 Research Institute At Nationwide Children's Hospital Optimized gene therapy targeting retinal cells
EP3990636A1 (de) 2019-06-28 2022-05-04 CRISPR Therapeutics AG Materialien und verfahren zur steuerung der geneditierung
CN114174514A (zh) 2019-07-25 2022-03-11 诺华股份有限公司 可调节的表达系统
MX2022002132A (es) 2019-08-21 2022-05-18 Res Inst Nationwide Childrens Hospital Administracion de vectores de virus adenoasociado de alfa-sarcoglicano y el tratamiento de la distrofia muscular.
EP4045092A1 (de) 2019-10-18 2022-08-24 Research Institute at Nationwide Children's Hospital Zielgerichtete cochlear-zellen-gentherapie
US20220389453A1 (en) 2019-10-18 2022-12-08 Research Institute At Nationwide Children's Hospital Materials and methods for the treatment of disorders associated with the irf2bpl gene
WO2021102435A1 (en) 2019-11-22 2021-05-27 Research Institute At Nationwide Children's Hospital Materials and methods for treatment of disorders associated with the ighmbp2 gene
EP4077687A1 (de) 2019-12-20 2022-10-26 Research Institute at Nationwide Children's Hospital Optimierte gentherapie zum targeting von muskeln bei muskelerkrankungen
CN115485382A (zh) 2020-02-18 2022-12-16 全国儿童医院研究所 X连锁病症的治疗中的AAV介导的MiRNA靶向
CN115379863A (zh) 2020-04-14 2022-11-22 吉尼松公司 用于治疗酸性神经酰胺酶缺乏症的载体
BR112022025586A2 (pt) 2020-06-15 2023-03-07 Res Inst Nationwide Childrens Hospital Liberação de vetor de vírus adenoassociado para distrofias musculares
WO2022018638A1 (en) 2020-07-21 2022-01-27 Crispr Therapeutics Ag Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
TW202227634A (zh) 2020-09-08 2022-07-16 美商薩羅塔治療公司 表現γ—肌聚醣之腺相關病毒載體之全身性遞送及肌肉失養症之治療
US20230357795A1 (en) 2020-09-15 2023-11-09 Research Institute At Nationwide Children's Hospital Aav-mediated homology-independent targeted integration gene editing for correction of diverse dmd mutations in patients with muscular dystrophy
JP2023543029A (ja) 2020-09-28 2023-10-12 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 筋ジストロフィーの治療のための製品及び方法
EP4222264A1 (de) 2020-09-30 2023-08-09 CRISPR Therapeutics AG Materialien und verfahren zur behandlung von amyotropher lateralsklerose
JP2023551279A (ja) 2020-11-30 2023-12-07 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 顔面肩甲上腕筋ジストロフィー（ｆｓｈｄ）を治療するための組成物及び方法
CA3205138A1 (en) 2020-12-17 2022-06-23 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
CA3209471A1 (en) 2021-01-27 2022-08-04 Research Institute At Nationwide Children's Hospital Materials and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
EP4288539A1 (de) 2021-02-03 2023-12-13 Research Institute at Nationwide Children's Hospital Zusammensetzungen und verfahren zur behandlung von erkrankungen im zusammenhang mit dux4-überexpression
WO2022170038A1 (en) 2021-02-05 2022-08-11 Amicus Therapeutics, Inc. Adeno-associated virus delivery of cln3 polynucleotide
JP2024508324A (ja) 2021-03-04 2024-02-26 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｍｄエクソンの重複を修正するためのｃｒｉｓｐｒ－ｃａｓ９を使用したジストロフィンベースのミオパチーの治療のための生成物及び方法
WO2022188797A1 (en) 2021-03-09 2022-09-15 Huigene Therapeutics Co., Ltd. Engineered crispr/cas13 system and uses thereof
EP4323010A1 (de) 2021-04-13 2024-02-21 Research Institute at Nationwide Children's Hospital Rekombinantes adeno-assoziiertes virus, das für methyl-cpg-bindendes protein 2 codiert, zur behandlung des pitt-hopkins-syndroms durch intrathekale verabreichung
JP2024515720A (ja) 2021-04-23 2024-04-10 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 筋ジストロフィーを治療するための製品及び方法
CA3218195A1 (en) 2021-05-07 2022-11-10 Robin Ali Abca4 genome editing
BR112023024078A2 (pt) 2021-05-17 2024-01-30 Sarepta Therapeutics Inc Produção de vetores de aav recombinantes para o tratamento de distrofia muscular
EP4108263A3 (de) 2021-06-02 2023-03-22 Research Institute at Nationwide Children's Hospital Rekombinante adeno-assoziierte virusprodukte und verfahren zur behandlung von gliedergürtel-muskeldystrophie 2a
AU2022290382A1 (en) 2021-06-11 2023-11-23 Bayer Aktiengesellschaft Type v rna programmable endonuclease systems
EP4101928A1 (de) 2021-06-11 2022-12-14 Bayer AG Programmierbare typ-v-rna-endonukleasesysteme
WO2023283962A1 (en) 2021-07-16 2023-01-19 Huigene Therapeutics Co., Ltd. Modified aav capsid for gene therapy and methods thereof
CA3228365A1 (en) 2021-08-11 2023-02-16 Solid Biosciences Inc. Treatment of muscular dystrophy
EP4144841A1 (de) 2021-09-07 2023-03-08 Bayer AG Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
CN117980484A (zh) 2021-09-16 2024-05-03 诺华股份有限公司 新颖的转录因子
CA3234702A1 (en) 2021-10-07 2023-04-13 Research Institute At Nationwide Children's Hospital Products and methods for myelin protein zero silencing and treating cmt1b disease
WO2023060233A1 (en) 2021-10-08 2023-04-13 Amicus Therapeutics, Inc. Biomarkers for lysosomal storage diseases
JP2023059858A (ja) 2021-10-15 2023-04-27 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 自己相補的アデノ随伴ウイルスベクター及び筋ジストロフィーの治療におけるその使用
JP2023081369A (ja) 2021-11-30 2023-06-09 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 自己相補的アデノ随伴ウイルスベクター及び筋ジストロフィーの治療におけるその使用
EP4198047A1 (de) 2021-12-16 2023-06-21 Genethon Erhöhung des gentransfers von fukutin-verwandtem protein unter verwendung modifizierter itr-sequenzen
EP4198134A1 (de) 2021-12-16 2023-06-21 Genethon Transfererhöhung des gamma-sarcoglycan-gens unter verwendung von modifizierten itr-sequenzen
EP4198046A1 (de) 2021-12-16 2023-06-21 Genethon Erhöhung des gentransfers von alpha-sarcoglykan unter verwendung von modifizierten itr-sequenzen
EP4198048A1 (de) 2021-12-16 2023-06-21 Genethon Calpain-3-gentransfersteigerung unter verwendung von modifizierten itr-sequenzen
WO2023122669A1 (en) 2021-12-21 2023-06-29 Research Institute At Nationwide Children's Hospital Materials and methods for the treatment of limb girdle muscular dystrophy
WO2023118068A1 (en) 2021-12-23 2023-06-29 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2023168400A2 (en) 2022-03-03 2023-09-07 Research Institute At Nationwide Children's Hospital Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefrom
WO2023196818A1 (en) 2022-04-04 2023-10-12 The Regents Of The University Of California Genetic complementation compositions and methods
WO2023214346A1 (en) 2022-05-06 2023-11-09 Novartis Ag Novel recombinant aav vp2 fusion polypeptides
WO2023240177A1 (en) 2022-06-08 2023-12-14 Research Instiitute At Nationwide Children's Hospital Products and methods for treating diseases or conditions associated with mutant or pathogenic kcnq3 expression
WO2023237587A1 (en) 2022-06-10 2023-12-14 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2024011115A1 (en) 2022-07-06 2024-01-11 Research Institute At Nationwide Children's Hospital Adeno-associated virus delivery of cln1 polynucleotide
WO2024035782A1 (en) 2022-08-10 2024-02-15 Aav Gene Therapeutics, Inc. Aav-mediated intramuscular delivery of insulin
WO2024081706A1 (en) 2022-10-11 2024-04-18 Research Institute At Nationwide Children's Hospital Adeno-associated virus delivery to treat spinal muscular atrophy with respiratory distress type 1 (smard1) and charcot-marie-tooth type 2s (cmt2s)
WO2024092126A1 (en) 2022-10-27 2024-05-02 Cargo Therapeutics, Inc. Compositions and methods for improved immunotherapies
WO2024129743A2 (en) 2022-12-13 2024-06-20 Bluerock Therapeutics Lp Engineered type v rna programmable endonucleases and their uses

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) * 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
WO1989007150A1 (en) * 1988-02-05 1989-08-10 The Trustees Of Columbia University In The City Of Retroviral packaging cell lines and processes of using same
US5278056A (en) * 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
JP3082204B2 (ja) * 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
EP0854193A1 (de) * 1990-09-21 1998-07-22 Chiron Corporation Humanische Retroviren- Packaging Zellinie
CA2096222C (en) * 1990-11-13 1998-12-29 Stephen D. Lupton Bifunctional selectable fusion genes
EP0572401B2 (de) * 1991-02-19 2007-11-07 The Regents of the University of California Viruspartikel mit veraendertem wirtspektrum
WO1994019478A1 (en) * 1993-02-22 1994-09-01 The Rockefeller University Production of high titer helper-free retroviruses by transient transfection
AU6953394A (en) * 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5378605A (en) 1993-06-08 1995-01-03 Thomas Jefferson University Method of detecting hepatitis B variants having deletions within the X region of the virus genome
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US5498537A (en) * 1994-03-09 1996-03-12 Cellco, Inc. Serum-free production of packaged viral vector
JPH10507905A (ja) * 1994-08-17 1998-08-04 ジェネティック セラピー インコーポレイテッド ヒト血清による溶解耐性生産者細胞系で生産されるレトロウイルスベクター

Also Published As

Publication number Publication date
ES2357736T3 (es) 2011-04-29
EP0871754A1 (de) 1998-10-21
CA2238436A1 (en) 1997-06-19
AU1354997A (en) 1997-07-03
DE69638334D1 (de) 2011-03-31
US5910434A (en) 1999-06-08
US6017761A (en) 2000-01-25
WO1997021825A1 (en) 1997-06-19
DK0871754T3 (da) 2011-05-30
CA2238436C (en) 2011-08-23
AU706543B2 (en) 1999-06-17
PT871754E (pt) 2011-05-10
EP0871754B1 (de) 2011-02-16
JP2000501944A (ja) 2000-02-22

Similar Documents

Publication Publication Date Title
ATE498689T1 (de) Methode für die produktion von retroviralen verpackungszellinien, die einen retroviralen überstand mit hocheffizienter transduktionsrate produzieren
ZA935915B (en) Modified fungal cells and method for producing recombinant products
ES8600783A1 (es) Procedimiento para la preparacion de la hormona polipeptidica factor de crecimiento de nervios de humano.
ATE242329T1 (de) Kombination von dna-sequenzen, die die bildung von modifizierter stärke in pflanzenzellen und pflanzen ermöglicht, verfahren zur herstellung dieser pflanzen
ATE313620T1 (de) Wirtszellen und methoden für die produktion von proteinen
ES8502476A1 (es) Un procedimiento para obtener polipeptidos similares a la hormona del crecimiento de ganado bovino
CA2241022A1 (en) Continuous process for producing membrane electrode composites (mea)
MXPA04004872A (es) Procedimiento para producir l-aminoacido utilizando escherichia.
CA2111845A1 (en) Monoclonal antibodies specific for marrow-derived mesenchymal cells
MY112803A (en) Deproteinized natural rubber latex and its production process
DE69636899D1 (de) Wirtszelle, die reduzierte mengen einer metalloprotease exprimiert und methoden zur verwendung dieser wirtszelle zur proteinproduktion
ATE117373T1 (de) Herstellung von guar-alpha-galactosidase mit durch rekombinante dns-verfahren transformierten wirtzellen.
HUT63652A (en) Process for producing cd44 surface protein variants, dna sequences encoding them and antibodies against them, as well as their application in diagnosis and therapy
EP0871718A4 (de) Herstellung enzymatisch aktiver, rekombinanter carboxypeptidase b
IT1255044B (it) Procedimento per produrre glicosiltransferasi, vettore ibrido di lievito in esso impiegato e ceppo di lievito trasformato con impiego di vettore ibrido
DE60027765D1 (de) Verfahren zur herstellung von mechanischer pulpe
ATE174630T1 (de) Expressionskassette, die einen aus dem schizosaccharomyces pombe-pho4-gene stammenden promotor enthält
HRP950506B1 (en) Method of producing starch decomposition products
DE3381843D1 (de) Verfahren zur herstellung eines herpes-antigens, dazu geeignetes mittel sowie verfahren zu seiner herstellung und die verwendung dieses antigens.
DE10348116A1 (de) CO-Generator
SI1456238T1 (sl) Proizvodnja f(ab)2 fragmentov v sesalskih celicah
DE69619681D1 (de) Verfahren zur herstellung von tabletten durch verpressung und durch dieses verfahren hergestellte tabletten
EP1058739A4 (de) Methode zur erstellung von genexpressionsprofilen
AU647795B2 (en) Method for preparing 1,1-dichloro-1-fluoroethane
DE69939876D1 (de) Methoden zur massenkultivierung von zellen die rekombinantes menschliches erythropoietin produzieren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0871754

Country of ref document: EP